Its role in post-treatment settings is less defined; however, the possibility of labelling PSMA with the beta-emitter 177Lu has opened a further therapeutic opportunity in prostate cancer patients whose effect can be evaluated by means of [68Ga]PSMA PET [75,76,77]. Here, FOLH1 is linked to prostate carcinoma.